Results 191 to 200 of about 9,301 (205)
Some of the next articles are maybe not open access.
A safety evaluation of raltegravir for the treatment of HIV
Expert Opinion on Drug Safety, 2017Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. Since its introduction in clinical practice RAL has become widely used for the treatment of HIV-1 infected patients. A decade after its approval, this article reviews key evidence from RAL with a special interest on safety outcomes ...
Natalia Stella-Ascariz +3 more
openaire +3 more sources
Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen [PDF]
Antiviral Therapy, 2013 Background We sought to determine the pharmacokinetic disposition of raltegravir in the blood and seminal plasma of HIV-infected men. Methods We conducted a pharmacokinetic study using a staggered sampling approach. A total of 16 HIV-infected men receiving raltegravir-based therapy were recruited into the study.
Charles la Porte +5 more
openaire +2 more sources
Raltegravir in pregnancy: a case series presentation
International Journal of STD & AIDS, 2011Adequate antiretroviral therapy is essential for HIV-positive pregnant women to prevent mother-to-child transmission. We report a small case series of five women receiving raltegravir as part of their antiretroviral regimen during pregnancy.
V Touzeau +7 more
openaire +3 more sources
Raltegravir in patients with tuberculosis
The Lancet Infectious Diseases, 2021Anton Pozniak, Graeme Meintjes
openaire +3 more sources
Pharmacokinetic and safety of raltegravir in pregnancy
European Journal of Clinical Pharmacology, 2012Dear Sirs:The aim of anti-HIV treatment in pregnancy is the suppres-sion of the HIV-1 RNA viral load in the plasma beforedelivery [1] to prevent mother-to-child transmission of theinfection. The achievement of this outcome may be compli-cated in pregnant women who have been treated with mul-tiple drugs by the lack of active drugs available ...
Maria Piera Riccardi +8 more
openaire +2 more sources
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
Antiviral Research, 2010Using quantitative deep HIV-1 sequencing in a subject who developed virological failure to deep salvage therapy with raltegravir, we found that most Q148R and N155H mutants detected at the time of virological failure originated from pre-existing minority Q148R and N155H variants through independent evolutionary clusters.
Rafael Delgado +12 more
openaire +4 more sources
Clinical Use of Raltegravir: A Review
HIV Therapy, 2010In the last 5 years there have been important achievements in the field of HIV therapy with the availability of new classes of antiretrovirals together with a new generation of old classes. Among them, the development of raltegravir, the first commercially available component of integrase inhibitors, brought an extraordinary improvement in salvage ...
Beatriz Grinsztejn +2 more
openaire +2 more sources
Variability of Raltegravir Plasma Levels in the Clinical Setting
Pharmacology, 2013Therapeutic drug monitoring of raltegravir C<sub>trough</sub> levels was carried out in the setting of the Raltegravir Switch for Toxicity or Adverse events (RASTA) trial, a randomized pilot study exploring a 48-week safety and efficacy of treatment switch to raltegravir associated with tenofovir/emtricitabine or abacavir/lamivudine in ...
Fortuna, Serena +6 more
openaire +5 more sources
New Raltegravir studies disappoint.
Journal watch. AIDS clinical care, 2011Excitement has been brewing about the use of once-daily raltegravir and also about the possibility that this integrase inhibitor could be paired with ...
openaire +3 more sources
Elvitegravir: a once daily alternative to raltegravir
The Lancet Infectious Diseases, 2012Rik Schrijvers +2 more
openaire +3 more sources